Daniela Gallo

Dr. Daniela Gallo

Endocrine Unit, ASST dei Sette Laghi, 21100 Varese, Italy
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
Maria Laura TandaMaria Laura Tanda
Maria Laura Tanda
EPE. Piantanida
E. Piantanida
LLL. Liparulo
L. Liparulo
GVGiovanni Veronesi
Giovanni Veronesi
ALA. Lai
A. Lai
LBL. Bartalena
L. Bartalena
The prevalence and natural history of Graves' orbitopathy (GO) are poorly documented. A large series of 346 patients with newly diagnosed and recent onset Graves' hyperthyroidism seen at a single (nontertiary referral) center over an 8-year period were enrolled in an observational prospective study and evaluated for GO activity and severity according to the EUGOGO (European Group on Graves' Orbitopathy) criteria. After excluding patients immediately treated for moderate-to-severe GO, patients undergoing total thyroidectomy or radioactive iodine treatment, and patients lost to follow-up, 237 patients were submitted to antithyroid drug (ATD) treatment, with ocular evaluation at 6, 12, and 18 months. Among the whole cohort, at presentation 255 (73.7%) had no ocular involvement, 70 (20.2%) had mild and inactive GO, 20 (5.8%) had moderate-to-severe and active GO, and 1 (0.3%) had sight-threatening GO with dysthyroid optic neuropathy. Of the 237 patients who completed the 18-month follow-up during or after ATD treatment, 194 (81.9%) had no GO at baseline. Progression to moderate-to-severe GO occurred in 5 (2.6%) of these patients. Of the 43 (18.1%) patients with mild and inactive GO at baseline, 1 (2.4%) progressed to moderate-to-severe GO, and 25 (58.1%) experienced complete remission. Most patients with newly diagnosed Graves' disease have no ocular involvement. Moderate-to-severe and active GO or sight-threatening GO are rare at presentation and rarely develop during ATD treatment. Most patients (>80%) with no GO at baseline do not develop GO after an 18-month follow-up period. Remission of mild GO occurs in the majority of cases.

12 March 2020 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
EPEliana Piantanida
Eliana Piantanida
SIS. Ippolito
S. Ippolito
DGDaniela Gallo
Daniela Gallo
EME. Masiello
E. Masiello
PPP. Premoli
P. Premoli
Maria Laura TandaMaria Laura Tanda
Maria Laura Tanda

26 June 2018 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
EME. Masiello
E. Masiello
GVGiovanni Veronesi
Giovanni Veronesi
DGDaniela Gallo
Daniela Gallo
PPP. Premoli
P. Premoli
EBE. Bianconi
E. Bianconi
LBLuigi Bartalena
Luigi Bartalena

27 July 2016 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
LBLuigi Bartalena
Luigi Bartalena
EME. Masiello
E. Masiello
FMF. Magri
F. Magri
GVGiovanni Veronesi
Giovanni Veronesi
EBE. Bianconi
E. Bianconi
LCL. Chiovato
L. Chiovato

4 March 2022 in Expert Review of Endocrinology & Metabolism
Verified
Journal Article
Closed access
LBLuigi Bartalena
Luigi Bartalena
EPEliana Piantanida
Eliana Piantanida
DGDaniela Gallo
Daniela Gallo
SISilvia Ippolito
Silvia Ippolito
Maria Laura TandaMaria Laura Tanda
Maria Laura Tanda
Graves’ disease (GD) is an autoimmune disorder due to loss of tolerance to the thyrotropin receptor (TSHR) and ultimately caused by stimulatory TSHR antibodies (TSHR-Ab). GD may be associated with ...

Verified
Journal Article
Open access
PDF file
DGDaniela Gallo
Daniela Gallo
DBDenisa Baci
Denisa Baci
NKNataša Kuštrimović
Nataša Kuštrimović
NLNicola Lanzo
Nicola Lanzo
BPBohdan Patera
Bohdan Patera
Lorenzo MortaraLorenzo Mortara
Lorenzo Mortara
Vitamin D is a secosteroid hormone that is highly involved in bone health. Mounting evidence revealed that, in addition to the regulation of mineral metabolism, vitamin D is implicated in cell proliferation and differentiation, vascular and muscular functions, and metabolic health. Since the discovery of vitamin D receptors in T cells, local production of active vitamin D was demonstrated in most immune cells, addressing the interest in the clinical implications of vitamin D status in immune surveillance against infections and autoimmune/inflammatory diseases. T cells, together with B cells, are seen as the main immune cells involved in autoimmune diseases; however, growing interest is currently focused on immune cells of the innate compartment, such as monocytes, macrophages, dendritic cells, and natural killer cells in the initiation phases of autoimmunity. Here we reviewed recent advances in the onset and regulation of Graves’ and Hashimoto’s thyroiditis, vitiligo, and multiple sclerosis in relation to the role of innate immune cells and their crosstalk with vitamin D and acquired immune cells.